Pathwork tissue test passes muster in multi-center investigation

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 4
Volume 18
Issue 4

A multi-institutional group has validated a predefined 1,550-gene expression profile for identifying tumor tissue of origin. Malignancies found in unexpected locations, or with poorly differentiated morphologies, can pose a challenge for tissue of origin determination.

A multi-institutional group has validated a predefined 1,550-gene expression profile for identifying tumor tissue of origin. Malignancies found in unexpected locations, or with poorly differentiated morphologies, can pose a challenge for tissue of origin determination.

Current histologic and imaging techniques fail to yield definitive identification, according to lead author Federico A. Monzon, MD and colleagues.

The group evaluated 547 frozen specimens representing 15 tissues of origin with the Pathwork Tissue of Origin Test, in which microarray technology measures gene expression pattern.

According to the study results, the test had an overall sensitivity of 87.8% and overall specificity of 99.4%. Performance within the subgroup of metastatic tumors (n = 258) was found to be slightly lower than that of the poorly differentiated and undifferentiated primary tumor subgroup, 84.5% and 90.7%, respectively (J Clin Oncol online, March 30, 2009).

 

Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content